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Abstract 
Exacerbations of disease are recognized now to be an important predictor of the unfavorable prognosis 
for patients with COPD. This research aimed to identify presence and type of inflammation in patients 
who were hospitalized due to COPD acute exacerbation, in order to recognize factors, associated with 
frequent hospital admission. The retrospective analysis of 162 case histories of patients hospitalized due 
to COPD acute exacerbation during three years’ period was carried out. The personal files of patients 
with single admission (group І – 112 persons) were separated from those who were hospitalized several 
times during three years’ period (group ІІ – 19 persons). Anthropometric parameters, including body 
mass index (BMI), data of post-bronchodilators’ pulmonary function tests (FEV1, FVC and FEV1/FVC), 
whole blood count, serum total and C-reactive protein, urine tests on time of admission to the in-patient 
unit were studied in all patients. The vast majority of patients with COPD acute exacerbation had clinical 
and laboratory signs of systemic inflammation. In more than in half cases it was neutrophilic 
(65.18 ± 4.50% and 57.89±11.33% in group I and II respectively), regardless the number of 
hospitalizations. Significantly higher C-reactive (11.51 ± 4.80 vs. 9.03 ± 3.58 mg/ml) and total (73.00 
[71,00-78,00] vs 69.00 [65.00-73.00] g/l) protein and a higher percentage of patients with an increased 
number of eosinophils (10.53 ± 7.04% vs 0.89 ± 0.89%) was found in group of patients who were 
hospitalized repeatedly compared with the group of hospitalized only once. Thus, high levels of C-
reactive protein, total protein and eosinophilia during exacerbations may be considered as predictors of 
frequent hospitalizations in patients with COPD. 
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1. Introduction  
Chronic obstructive pulmonary disease (COPD) is one of the major causes of morbidity, and it 
was the third leading cause of mortality worldwide in 2010 [1]. Exacerbations of disease are 
recognized now to be an important predictor of the unfavorable prognosis for patients with 
COPD [2, 3]. Small portion of patients suffering from frequent exacerbations (approximately 
10%), accounting for more than 70% of the total cost of COPD treating due to need to stay in 
hospital and emergency care [4]. In the year of 2005 it was estimated that COPD exacerbations 
cost 38 billion dollars to the US health care system [5]. 
Re-hospitalizations due to COPD exacerbation call for special attention, because it has been 
established that expenditures in re-hospitalization are significantly greater than in case of 
initial hospital stay [6]. On average, costs for a 30-day readmission with COPD as principal 
diagnosis ($8,400) were 18 percent higher than for the index stay ($7,100). Costs were more 
than 50 percent higher for the readmission with COPD as any diagnosis ($10,900) or for all-
cause readmissions ($11,100) [6]. 
The COPD exacerbations exceptional significance was reflected in the GOLD, 2011 [7]. In this 
document, even in the definition of COPD, stressed that exacerbations and comorbidities 
significantly affect the severity of diseases in some individuals. In addition, in GOLD, 2014 
not only number of exacerbations, but also number of hospitalizations during the past year has 
been recognized as one of the main criteria for the patients’ future risks detection [8]. A similar 
approach was adopted in Order number 555 of the Ministry of Health of Ukraine (June 27, 
2013) [9], which now governs the provision of medical care to patients with COPD in our 
country. Nevertheless, since in some cases re-hospitalization could be avoided, it is important 
to determine predictors of returning to the hospital due to COPD exacerbation. Their 
identification seems to be useful for planning the future medical intervention strategy in 
patients with COPD. This strategy may include either increasing the dose of medication that  
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the patient is already receiving, or prescription of additional 
drugs, i.e. anti-inflammatory agents. Meanwhile, existing 
criteria predict probability of re-hospitalization due to COPD 
exacerbation too approximately. At the same time, in order to 
react to possible worsening of the patient’s condition 
effectively, practitioners should have a simple and reliable way 
of predicting the probability of the hospitalization.  
Since systemic inflammation is one of the leading mechanisms 
of COPD occurrence and progression, and its expression can 
greatly influence the nature and extent of medical intervention 
in disease [7-12], this research aimed to identify presence and 
type of inflammation in patients who were hospitalized due to 
COPD acute exacerbation, in order to recognize factors, 
associated with frequent hospital admission. 
 
2. Material and methods 
The retrospective analysis of case histories of patients 
hospitalized to therapeutic unit in Municipal establishment 
“Dnipropetrovsk clinical hospital №6” of Dnipropetrovsk 
Regional Council” during three years’ period was carried out. 
Inclusion criterion for analysis of chosen case histories was 
verified diagnosis «COPD exacerbation» according to the 
Order №128 of Ministry of Health of Ukraine from 19.03.2007 
[13], taking into account findings of post-bronchodilatation 
spirometry according to international standards of quality and 
recommendations of Ukrainian scientists [14, 15]. Criterion for 
case histories exclusion was presence of clinical-X-ray signs 
of pulmonary infiltration, pulmonary atelectasis or the pleural 
effusion in time of hospitalization. 
During the analysis the personal files of patients with single 
admission were separated from those who were hospitalized 
several times during three years’ period. Anthropometric 
parameters, including body mass index (BMI), data of post-
bronchodilators’ pulmonary function tests (FEV1, FVC and 
FEV1/FVC), whole blood count, serum total and C-reactive 
protein, urine tests on time of admission to the in-patient unit 
were studied in all patients. 
The results obtained were processed using descriptive and 
analytical statistics by means of «STATISTICA 6.1» program 
[16]. Number of observations (n) was calculated for all findings. 
Mean values (M) for quantitative signs and root-mean 
deviations (± SD) under conditions of a normal distribution or 
median (Ме) and upper and lower quartiles ([25-75%]) under 
conditions of abnormal distribution of findings were defined. 
Qualitative signs were presented in the form of absolute values 
(n) and relative frequencies (P), expressed in the share of unit 
or in percentage (%), with marking of an error (± m). 
Significance of differences in quality parameters was 
evaluated mostly by chi-square (χ2) and when n < 5 – by 
Fisher's exact criterion for frequency. The correlation between 
indicators (quantitative, qualitative) was assessed using 
Spearman correlation coefficient (R) regardless of their 
distribution. To assess the significance of differences between 
correlation coefficients in the two groups the "correlation 
coefficients for errors’ test" was used. For analysis of all types 
findings differences between the groups were considered to be 
significant if р < 0.05. 
 
3. Results and discussion 
162 case histories with diagnosis of COPD exacerbation 
requiring hospitalization, confirmed by clinical, anamnestic 
and spirometry findings, were selected for the final analysis. 
Detailed study elucidated that in 112 cases (69.14 ± 3.63%) 
patients were hospitalized only one time during three years’ 
period. However, almost third part of hospital stay due to 
COPD exacerbation, 50 (30.86 ± 3.63%), was caused by 
hospitalization of the same persons. So, we separate two 
groups of patients: group І (112 persons) – hospitalized one 
time and group ІІ (19 persons) – hospitalized due to COPD 
exacerbation two or more times during three years’ period.  
In accordance with retrospective analysis data (Table 1), both 
groups were similar regarding to age, sex and anthropometric 
characteristics.  
The vast majority of hospitalizations in both groups were 
associated most likely with infectious exacerbation. It was 
evidenced by the presence of fever at the time of hospital 
admission in approximately 9/10 of patients both in group I 
and in group II. 
 
 
Table 1: Anthropometric data and clinical and laboratory signs of systemic inflammation in patients who were hospitalized due to exacerbation 
of COPD 
 
Indexes Group І (n = 112) 
Group ІI* 
(n = 19) р 
Sex: men, n (Р [95 % CI]) 
2) women, n (Р [95 % CI]) 
79(0.71 [0.62-0.78]) 
33(0.29 [0.22-0.38]) 
16 (0.84 [0.60-0.96]) 
3(0.16 [0.05-0.40]) 
0.239 
0.239 
Age Med [25%-75%], years 65.00 [55.00-69.00] 59.00 [53.00-73.00] 0.882 
Height M ± SD, cm 169.45 ± 8.46 171.26 ± 8.01 0.387 
Weight Med [25%-75%], kg 75.00 [69.00-85.00] 70.00 [60.00-90.00] 0.253 
BMI Med [25%-75%], kg/m2 26,12 [23,62-29,73] 25,71 [20,78-28,38] 0,137 
Fever, n (Р ± m %) 108(96.43 ± 1.75) 17(89.7 ± 7.04) 0.209 
Total serum protein, Med [25%-75%], g/l 69.00[65.00-73.00] 73.00[71,00-78,00] 0.017 
Serum C-reactive protein, M ± SD, mg/l 9.03 ± 3.58 11.51 ± 4.80 0.012 
White blood cells, Med [25%-75%], *109 cells/l 11.80[10.50-12.90] 12.20[9.90-13.70] 0.849 
Type of inflammation (in accordance with whole blood count): 
Neutrophilic, n(Р ± m %)Eosinophilic, n(Р ± m %) 
Lymphocytic, n(Р ± m %)Monocytic or basophilic, n 
(Р ± m %)No inflammation, n(Р ± m %) 
73(65.18 ± 4.50) 
1(0.89 ± 0.89) 
24(21.43 ± 3.88) 
0(0 ± 0,00) 
15(13.39 ± 3.22) 
11(57.89±11.33) 
2(10.53 ± 7.04) 
3(15.79 ± 8.37) 
0(0 ± 0,00) 
3(15.79 ± 8.37) 
0.235 
0.009 
0.416 
1.000 
0.506 
 
Note. * – data of the group ІІ concern first registered hospitalization. 
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Plasma C-reactive protein was higher than 5 mg/l (upper limit 
of normal ranges in the local laboratory) in majority of patients 
of both groups: in 75 (66.96 ± 4.44%) cases in group I and in 
16 (84.21 ± 8.37%) – in group II (Figure 1). This indicates the 
presence of systemic inflammation’s signs during COPD acute 
exacerbations in the most of patients, admitted to the 
therapeutic unit. Number of persons with C-reactive protein 
which exceed normal ranges was higher in group II, although 
the difference with group I was not statistically significant 
(p = 0.131). However, the average level of C-reactive protein 
was significantly higher in patients who admitted to the 
hospital due to COPD exacerbation many times (Table 1). 
Therefore abnormal serum C-reactive protein during 
exacerbation could be considered as a possible predictor of 
repeated hospitalization in patients with COPD. 
 
 
 
Fig 1: Proportion of patients with normal and high serum C-
reactive protein in groups 
 
Total protein in serum was determined in all patients at the 
beginning of hospitalization. According to a retrospective 
analysis data, none of the patients in both groups had elevated 
total protein level. At the same time, hypoproteinemia was 
observed in 20 (17.86 ± 3.62%) cases of group I and in 2 
(10.53 ± 7.04%) of group II (p = 0.340). However, significant 
proteinuria was not found in urinalysis in any of the patients, 
regardless of group. In this reason, decreasing of total protein 
in some patients cannot be explained by loss of protein due to 
kidney damage. Unfortunately, there were no data of detailed 
blood protein spectrum in case histories, so we can only 
assume that hypoproteinemia, even against the background of 
systemic inflammation, was caused by significant catabolic 
processes in the body of some patients with acute exacerbation 
of COPD. This assumption was confirmed by the fact that in 
the group of patients who had been hospitalized several times 
over three years, the level of total protein significantly 
(p = 0.027) moderate (R = 0.609) correlated with body BMI. I 
general the median level of total serum protein in both groups 
although were within normal limits, but nevertheless were 
significantly higher in group II (Table 1). These results require 
further investigations and may be clarified only after detailed 
qualitative serum protein analysis in patients with acute 
exacerbation of COPD. 
Whole blood count investigation had found the high white 
blood cells level in 96 (85.71 ± 3.31%) patients of group I and 
in 16 (84.21 ± 8.37%) patients of group II. It confirms the 
hypothesis of infectious nature of COPD acute exacerbation in 
most hospitalized patients. At the same time the number of 
leukocytes in peripheral blood was within the normal ranges in 
approximately 15% of patients in both groups. No case of 
leucopenia either in group I, or in group II was recorded. 
Overall, the median total number of white blood cells 
exceeded the normal values in each of group, but the 
difference between this parameter in group I and II was not 
statistically significant.  
As the systemic inflammation implemented with the 
participation of many cells during COPD acute exacerbation, it 
was appropriate to determine the type of inflammation 
evaluating the number of neutrophils, eosinophils, 
lymphocytes, monocytes and basophils in whole blood count 
(Table 1). 
None of the patients has increased or decreased basophils and 
monocytes number regardless of the group. At the same time, 
nearly one in five patients in groups I and one in six in group 
II had lymphocytosis, which apparently was associated with 
acute viral infection as a likely factor that provoked 
exacerbation. The most numerous were patients with a high 
percentage of neutrophilic leukocytes, regardless the group to 
which they belonged. This fact probably reflects the bacterial 
nature of COPD acute exacerbation. The information that 
needs attention is significantly larger share of patients with 
eosinophilic type of systemic inflammation in the group with 
recurrent hospitalization, while in the group I there was only 
one patient with blood eosinophilia. Therefore, one should pay 
attention to the elevated levels of eosinophils in the peripheral 
blood when determining the possible predictors of re-
hospitalization due to COPD exacerbation. 
 
4. Conclusions 
1. The vast majority of patients with COPD acute 
exacerbation had clinical and laboratory signs of systemic 
inflammation. In more than in half cases it was 
neutrophilic (65.18 ± 4.50% and 57.89±11.33% in group I 
and II respectively), regardless the number of 
hospitalizations. 
2. Significantly higher C-reactive (11.51 ± 4.80 vs. 9.03 ± 
3.58 mg/ml) and total (73.00 [71,00-78,00] vs 69.00 
[65.00-73.00] g/l) protein and a higher percentage of 
patients with an increased number of eosinophils (10.53 ± 
7.04% vs 0.89 ± 0.89%) was found in group of patients 
who were hospitalized repeatedly compared with the 
group of hospitalized only once. Thus, high levels of C-
reactive protein, total protein and eosinophilia during 
exacerbations may be considered as predictors of frequent 
hospitalizations in patients with COPD. 
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